Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)
The guidance now specifies that documentation for clinical investigation submissions must include comprehensive safety and performance data to meet MHRA assessment requirements.
This update ensures compliance with the UK Medical Device Regulations 2002, impacting the readiness of clinical safety teams to submit accurate and complete safety data, which is essential for the assessment and approval of clinical investigations.
Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Clarified safety data requirements for device clinical investigation submissions; updated submission process for MHRA assessment.
The revised guidance dictates how manufacturers must prepare and submit safety data for medical device clinical investigations in the UK. This impacts clinical safety teams' processes for compiling safety reporting and clinical data for MHRA review, ensuring compliance with the UK Medical Device Regulations 2002.
Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.
The Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance regarding documentation requirements for clinical investigations. This includes clarity on safety data needed for the assessment of medical devices, affecting the processes of clinical safety teams responsible for compiling safety reporting and clinical data for MHRA review.
What changed: The guidance now specifies that documentation for clinical investigation submissions must include comprehensive safety and performance data to meet MHRA assessment requirements.
Why it matters: This update ensures compliance with the UK Medical Device Regulations 2002, impacting the readiness of clinical safety teams to submit accurate and complete safety data, which is essential for the assessment and approval of clinical investigations.
Practical implication: Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
